Oxcarbazepine

Research use only, not for human use.

Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group.

Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat partial seizures in epileptic children and adults. (In Vitro):Oxcarbazepine significantly inhibits glioblastoma cell growth and reaches IC50 at therapeutic concentrations. The IC50s of Oxcarbazepine screened with the U87 and T98 cell lines are 12.35 and 9.45 μg/mL,respectively.(In Vivo):Oxcarbazepine protectes mice and rats against generalized tonic-clonic seizures induced by electroshock with ED50 values between 13.5 and 20.5 mg/kg p.o. No tolerance toward this anticonvulsant effect is observed when rats are treated with Oxcarbazepine daily for 4 weeks.

Oxcarbazepine significantly inhibits glioblastoma cell growth and reaches IC50 at therapeutic concentrations. The IC50s of Oxcarbazepine screened with the U87 and T98 cell lines are 12.35 and 9.45 μg/mL,respectively. Cell Viability Assay Cell Line:Human glioma cell lines U-87 MG and T98G Concentration:2.5, 5, 10, 20, and 40 μg/mL Incubation Time:72 hours Result:The growth inhibition for the T98G cell line for each concentration was 17.7±4.1% (2.5 μg/mL), 21.1±3.6% (5 μg/mL), 53.6±14.2% (10 μg/mL), 82.2±2.3% (20 μg/mL), and 85.0±2.3% (40 μg/mL).The growth inhibition for U-87 MG cell line for each concentration was ?1.7±5.1% (0.008 μg/mL), 5.3±2.4% (0.08 μg/mL), 3.5±7.4% (0.8 μg/mL), 0.3±9.2% (16 μg/mL), and ?4.2±9.6% (40 μg/mL).

Oxcarbazepine protectes mice and rats against generalized tonic-clonic seizures induced by electroshock with ED50 values between 13.5 and 20.5 mg/kg p.o. No tolerance toward this anticonvulsant effect is observed when rats are treated with Oxcarbazepine daily for 4 weeks.

GP47680

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

Neurological Disease

——

28721-07-5

252.27

C15H12N2O2

>98% (HPLC)

DMSO: 7 mg/mL (27.74 mM)

O=C(C1=CC2=CC=CCC2=[N+]([O-])C3=CC=CC=C13)N

5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide

(-20℃)

With Ice Pack

≥ 2 years